EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis

Shuhong Ye iD, Biao Yu, Jiawen Wu, Zining Xu, Bingyang Xu, Hong Sun, Bin Zhao

Dermatitis® · 2024

DOI: 10.1089/derm.2023.0298 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Dermatitis®, 2024. Verfasst von Shuhong Ye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China. Hauptthemen laut MEDLINE: Psoriasis, Heterocyclic Compounds, 3-Ring, Interleukin-17, Eczema. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHeterocyclic Compounds, 3-RingInterleukin-17EczemaHumansJanus Kinase 1Janus Kinase InhibitorsAntibodies, Monoclonal, HumanizedFemale

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingInterleukin-17Janus Kinase 1Janus Kinase InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
  • Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Department of Neurology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
  • Department of Dermatology, Xi'an International Medical Center Hospital, Xi'an, China.

ORCID-Profile: Shuhong Ye

Zitieren

APA

Ye, S., Yu, B., Wu, J., Xu, Z., Xu, B., Sun, H., & Zhao, B. (2024). Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis. Dermatitis®. https://doi.org/10.1089/derm.2023.0298

Vancouver

Ye S, Yu B, Wu J, Xu Z, Xu B, Sun H, et al. Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis. Dermatitis®. 2024. doi:10.1089/derm.2023.0298

BibTeX
@article{Ye2024,
  author = {Ye, Shuhong and Yu, Biao and Wu, Jiawen and Xu, Zining and Xu, Bingyang and Sun, Hong and Zhao, Bin},
  title = {Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis},
  journal = {Dermatitis®},
  year = {2024},
  doi = {10.1089/derm.2023.0298}
}
Kostenlos starten →